Utilizing Interpretable AI to Distinguish prePMF From ET
December 10th 2023Andrew Srisuwananukorn, MD, discusses the main findings from research of an artificial intelligence-powered machine learning algorithm which evaluated digital whole-slide images of diagnostic bone marrow biopsies and accurately differentiated prefibrotic primary myelofibrosis from essential thrombocythemia.
Watch
Graff on Using the Signatera Assay to Assess ctDNA in Early Breast Cancer
December 8th 2023Stephanie L. Graff, MD, discusses what a community oncologist should know about her presentation on the Signatera assay in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer after adjuvant abemaciclib and endocrine therapy.
Watch
Safety Data From the Phase 2B SunRISe-2 Study of TAR-200 in BCG-Unresponsive High-Risk NMIBC
December 7th 2023The TAR-200 treatment has demonstrated a favorable safety profile in clinical trial, with primarily low-grade irritated voiding symptoms that are manageable and expected with intravesical therapy, without concerning systemic side effects, making it a promising new option to delay or reduce radical cystectomy in patients with BCG-unresponsive NMIBC.
Watch
Overview of the Mechanism of Action of TAR-200 in Patients With BCG-Unresponsive High-Risk NMIBC
December 7th 2023The TAR-200 treatment for BCG-unresponsive NMIBC works through a catheter-placed intravesical device that elutes gemcitabine over 3 weeks, providing a high complete response rate of 77% in early testing, likely due to the sustained release mechanism.
Watch